Stability of the Transthyretin Molecule as a Key Factor in the Interaction with A-Beta Peptide - Relevance in Alzheimer's Disease

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ribeiro, Carlos A ^a,b   Saraiva, Maria João ^a,b   Cardoso, Isabel ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,5 DICHLOROPHENYL)AMINO; 4 (3,5 DIFLUOROPHENYL); AMYLOID BETA PROTEIN; FLUFENAMIC ACID; GENISTEIN; PREALBUMIN; THYROXINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DOT HYBRIDIZATION; HUMAN; HUMAN CELL; OLIGOMERIZATION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; CELL LINE, TUMOR; DIFLUNISAL; DINITROPHENOLS; HUMANS; MUTATION; PHTHALIC ACIDS; PREALBUMIN; PROTEIN BINDING; STILBENES;

EID: 84866460552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045368     Document Type: Article

References (46)

1. Association As, (2010) 2010 Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association 6: 158-194.
2. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR, (1995) An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clinical anatomy 8: 429-431.
3. Boutajangout A, Leroy K, Touchet N, Authelet M, Blanchard V, et al. (2002) Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1. Neuroscience letters 318: 29-33.
4. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, et al. (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proceedings of the National Academy of Sciences of the United States of America 91: 8368-8372.
5. Choi SH, Leight SN, Lee VM, Li T, Wong PC, et al. (2007) Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). The Journal of neuroscience: the official journal of the Society for Neuroscience 27: 7006-7010.
6. Costa R, Goncalves A, Saraiva MJ, Cardoso I, (2008) Transthyretin binding to A-Beta peptide-impact on A-Beta fibrillogenesis and toxicity. FEBS letters 582: 936-942.
7. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I, (2008) Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. PLoS One 3: e2899.
8. Lashuel HA, Lai Z, Kelly JW, (1998) Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 37: 17851-17864.
9. Nilsson SF, Peterson PA, (1971) Evidence for multiple thyroxine-binding sites in human prealbumin. The Journal of biological chemistry 246: 6098-6105.
10. Blake CC, Swan ID, Rerat C, Berthou J, Laurent A, et al. (1971) An x-ray study of the subunit structure of prealbumin. Journal of molecular biology 61: 217-224.
11. Monaco HL, Rizzi M, Coda A, (1995) Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268: 1039-1041.
12. McCutchen SL, Colon W, Kelly JW, (1993) Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 32: 12119-12127.
13. Baures PW, Peterson SA, Kelly JW, (1998) Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorganic & medicinal chemistry 6: 1389-1401.
14. Oza VB, Smith C, Raman P, Koepf EK, Lashuel HA, et al. (2002) Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. Journal of medicinal chemistry 45: 321-332.
15. Furuya H, Saraiva MJ, Gawinowicz MA, Alves IL, Costa PP, et al. (1991) Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP). Biochemistry 30: 2415-2421.
16. Almeida MR, Damas AM, Lans MC, Brouwer A, Saraiva MJ, (1997) Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine 6: 309-315.
17. Magalhaes J, Santos SD, Saraiva MJ, (2010) alphaB-crystallin (HspB5) in familial amyloidotic polyneuropathy. International journal of experimental pathology 91: 515-521.
18. Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, et al. (2004) Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. The Biochemical journal 381: 351-356.
19. Liz MA, Faro CJ, Saraiva MJ, Sousa MM, (2004) Transthyretin, a new cryptic protease. The Journal of biological chemistry 279: 21431-21438.
20. Altland K, Rauh S, Hacker R, (1981) Demonstration of human prealbumin by double one-dimensional slab gel electrophoresis. Electrophoresis 2: 148-155.
21. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, et al. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Molecular neurodegeneration 2: 18.
22. Cardoso I, Almeida MR, Ferreira N, Arsequell G, Valencia G, et al. (2007) Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. The Biochemical journal 408: 131-138.
23. Ferreira N, Saraiva MJ, Almeida MR, (2011) Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS letters 585: 2424-2430.
24. Potter MA, Luxton G, (1999) Prealbumin measurement as a screening tool for protein calorie malnutrition in emergency hospital admissions: a pilot study. Clinical and investigative medicine Medecine clinique et experimentale 22: 44-52.
25. Velayudhan L, Killick R, Hye A, Kinsey A, Guentert A, et al. (2011) Plasma Transthyretin as a Candidate Marker for Alzheimer's Disease. Journal of Alzheimer's disease: JAD.
26. Serot JM, Christmann D, Dubost T, Couturier M, (1997) Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. Neurosurg Psychiatry 63(4): 506-508.
27. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, et al. (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 91(18): 8368-8372.
28. Schwarzman AL, Goldgaber D, (1996) Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. Ciba Found Symp 199: 146-160.
29. Stein TD, Johnson JA, (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. The Journal of neuroscience: the official journal of the Society for Neuroscience 22: 7380-7388.
30. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, et al. (1996) Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proceedings of the National Academy of Sciences of the United States of America 93: 15051-15056.
31. Sekijima Y, Dendle MA, Kelly JW, (2006) Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 13: 236-249.
32. Morais-de-Sa E, Pereira PJ, Saraiva MJ, Damas AM, (2004) The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. The Journal of biological chemistry 279: 53483-53490.
33. Baures PW, Oza VB, Peterson SA, Kelly JW, (1999) Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorganic & medicinal chemistry 7: 1339-1347.
34. Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, et al. (1998) Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proceedings of the National Academy of Sciences of the United States of America 95: 12956-12960.
35. Raghu P, Reddy GB, Sivakumar B, (2002) Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization. Archives of biochemistry and biophysics 400: 43-47.
36. Trivella DB, Bleicher L, Palmieri L C, Wiggers HJ, Montanari CA, et al. (2010) Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding. Journal of structural biology 170: 522-531.
37. Radovic B, Mentrup B, Kohrle J, (2006) Genistein and other soya isoflavones are potent ligands for transthyretin in serum and cerebrospinal fluid. The British journal of nutrition 95: 1171-1176.
38. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ, (2010) Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. Journal of translational medicine 8: 74.
39. Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ, (2008) Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochimica et biophysica acta 1782: 517-522.
40. Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, et al. (2009) Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS letters 583: 3569-3576.
41. Ferreira N, Saraiva MJ, Almeida MR, (2012) Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models. PLoS One 7: e29933.
42. Miyata M, Sato T, Kugimiya M, Sho M, Nakamura T, et al. (2010) The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry 49: 6104-6114.
43. Liz MA, Fleming CE, Nunes AF, Almeida MR, Mar FM, et al. (2009) Substrate specificity of transthyretin: identification of natural substrates in the nervous system. Biochem J 419(2): 467-474.
44. Shoji S, Nakagawa S, (1988) Serum prealbumin and retinol-binding protein concentrations in Japanese-type familial amyloid polyneuropathy. European neurology 28: 191-193.
45. Filteau SM, Willumsen JF, Sullivan K, Simmank K, Gamble M, (2000) Use of the retinol-binding protein: transthyretin ratio for assessment of vitamin A status during the acute-phase response. The British journal of nutrition 83: 513-520.
46. Palha JA, Moreira P, Wisniewski T, Frangione B, Saraiva MJ, (1996) Transthyretin gene in Alzheimer's disease patients. Neuroscience letters 204: 212-214.